Mexiprim solution 50mg/ml 5ml 5pcs

Composition

Composition per 1 ml:

Ethylmethylhydroxypyridine succinate — 50 mg

Water for injection-up to 1 ml

Pharmacological action

Mexiprim is a heteroaromatic antioxidant. It has a wide range of pharmacological activity: increases the body’s resistance to stress, shows an anxiolytic effect that is not accompanied by drowsiness and muscle relaxant effect; has nootropic properties, prevents and reduces learning and memory disorders that occur during aging and exposure to various pathogenic factors; has an anticonvulsant effect; shows antioxidant and antihypoxic properties; increases concentration and performance; weakens the toxic effect of alcohol. The drug improves the metabolism of brain tissues and their blood supply, improves microcirculation and rheological properties of blood, reduces platelet aggregation. Stabilizes the membrane structures of blood cells (red blood cells and platelets). It has a hypolipidemic effect, reduces the content of total cholesterol and low-density lipoproteins. The mechanism of action of Mexiprim is due to its antioxidant and membrane-protective action. It inhibits lipid peroxidation, increases the activity of superoxide oxidase, increases the lipid-protein ratio, reduces the viscosity of the membrane, and increases its fluidity. Modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional organization of biomembranes, transport neurotransmitters, and improve synaptic transmission. Mexiprim increases the level of dopamine in the brain. It causes an increase in compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of ATP and creatine phosphate, activation of energy-synthesizing functions of mitochondria, and stabilization of cell membranes. Pharmacokinetics The maximum concentration of Mexiprim in blood plasma is in the range from 50 to 100 ng / ml. The half-life of Mexiprim and the average retention time of the drug in the body are 4.7-5.0 hours and 4.9-5.2 hours, respectively. Mexiprim is intensively metabolized in the human body with the formation of its glucuronoconjugated product. On average,0.3% of the unchanged drug and 50% in the form of glucuronoconjugate of the administered dose are excreted in the urine for 12 hours. Mexiprim and its glucuronoconjugate are most intensively excreted during the first 4 hours after taking the drug. Urinary excretion rates of Mexiprim and its conjugated metabolite are highly variable individually.

Indications

• Acute disorders of cerebral circulation (as part of complex therapy);
• Dyscirculatory encephalopathy;
• Vegetative-vascular dystonia;
• Anxiety states in neurotic and neurosis-like states;
• Mild cognitive disorders of various origins (psychoorganic and asthenic syndromes, consequences of traumatic brain injuries, atherosclerosis, senile and atrophic processes, neuroinfections and intoxication);
• Memory disorders and intellectual disability in the elderly;
• Exposure to extreme (stressful) factors;
• Withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;
• Acute intoxication with antipsychotic drugs.

Contraindications

Acute hepatic and / or renal insufficiency, increased individual sensitivity to the drug. Childhood, pregnancy, breast-feeding — due to insufficient knowledge of the drug’s effect in these categories of patients.

Side effects

Rarely — nausea, dryness of the oral mucosa, drowsiness, allergic reactions.

Interaction

Compatible with psychotropic drugs.

Increases the effect of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), antiparkinsonian agents (levodopa), reduces the toxic effect of ethyl alcohol.

How to take, course of use and dosage

Mexiprim is administered intramuscularly or intravenously (jet or drip). Doses are selected individually. With the infusion method of use, the drug should be diluted in saline sodium chloride solution. Start treatment with a dose of 50-100 mg 1-3 times a day, gradually increasing the dose until a therapeutic effect is obtained. Jet Mexiprim is administered slowly for 5-7 minutes, drip-at a rate of 40-60 drops per minute. The maximum daily dose does not exceed 800 mg. In acute disorders of cerebral circulation, Mexiprim is used in complex therapy for the first 2-4 days intravenously drip 200-300 mg 1 time a day, then intramuscularly 100 mg 3 times a day. The duration of treatment is 10-14 days. In case of dyscirculatory encephalopathy in the decompensation phase, Mexiprim should be administered intravenously by jet or drip at a dose of 100 mg 2-3 times a day for 14 days. Then the drug is administered intramuscularly at 100 mg 2-3 times a day for the next 2 weeks. For the course prevention of dyscirculatory encephalopathy, the drug is administered intramuscularly at a dose of 100 mg 2 times a day for 10-14 days. For mild cognitive impairment in elderly patients and anxiety disorders, the drug is used intramuscularly at a daily dose of 100-300 mg per day for 14-30 days. With alcohol withdrawal syndrome, Mexiprim is administered at a dose of 100-200 mg intramuscularly 2-3 times a day or intravenously 1-2 times a day for 5-7 days. In acute intoxication with antipsychotic drugs, the drug is administered intravenously at a dose of 50-300 mg per day for 7-14 days.

Overdose

Symptoms: sleep disorders (insomnia, in some cases — drowsiness). Treatment: as a rule, it is not required — the symptoms disappear on their own within a day. In severe cases of insomnia, it is recommended to take sleeping pills.

Special instructions

During the treatment period, care should be taken when driving vehicles and engaging in other potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.

Form of production

The solution for intravenous and intramuscular use is colorless or slightly yellowish, transparent.

Storage conditions

In a place protected from light at a temperature not exceeding 20°C. Keep out of reach of children.

Shelf

life is 3 years.

Active ingredient

Ethylmethylhydroxypyridine Succinate

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection and infusion

Description

For adults as directed by your doctor

Indications

Neurosis, Hangover, Exposure to adverse factors, Stroke effects, Acquired dementia, Concussion and other traumatic brain injuries, Vegetative-vascular disorders, Cerebral circulation disorders, Atherosclerosis